Clinical Trial: NCT04195750
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | Merck Sharp & Dohme LLC |
| Information Provided By: | Merck Sharp & Dohme LLC |
| Last Update Posted: | 2026-10-20 |
Study Overview
Brief Summary
The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is that belzutifan is superior to everolimus with respect to PFS and OS.
Official Title
Conditions
Intervention / Treatment
- Drug: Belzutifan
- Drug: Everolimus
Other Study ID Numbers
- 6482-005
- MK-6482
- 205262
- jRCT2080225166
- 2023-506635-15-00
- U1111-1294-1321
- 2019-003444-72
- 2019
- 2023
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Merck Sharp & Dohme LLC |
| Information Provided By: | Merck Sharp & Dohme LLC |
| Last Update Posted: | 2026-10-20 |
Study Overview
Brief Summary
The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is that belzutifan is superior to everolimus with respect to PFS and OS.
Official Title
Conditions
Intervention / Treatment
- Drug: Belzutifan
- Drug: Everolimus
Other Study ID Numbers
- 6482-005
- MK-6482
- 205262
- jRCT2080225166
- 2023-506635-15-00
- U1111-1294-1321
- 2019-003444-72
- 2019
- 2023